Response to vedolizumab for children with steroid‐refractory Ulcerative Colitis unresponsive to anti‐<scp>TNF</scp>

Wiskin, Anthony E.; Paul, Siba Prosad; Spray, Christine

doi:10.1111/apa.14765

Cited by 2 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These previously mentioned studies only reported short-term experiences with vedolizumab use (1 year follow-up at the most). Another study, performed in Bristol, United Kingdom, reporting data on four children with UC showed clinical remission in two patients after week 6 lasting during the 2 year follow-up without adverse effects 6…”

Section: Discussionmentioning

confidence: 97%

“…Vedolizumab is a humanised α4β7-integrin antagonist, which inhibits T-lymphocyte migration into inflamed intestinal tissue down-regulating intestine inflammation mediated by UC. However, it is currently an off-label alternative to treat paediatric patients and there is little data on its long-term use and its use to treat the youngest children 2–7…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Successful long-term treatment of paediatric ulcerative colitis with vedolizumab: a case report

et al. 2022

View full text Add to dashboard Cite

Biologics are recommended to treat paediatric ulcerative colitis (UC) that is chronically active or steroid-dependent despite aminosalicylic acids (5-ASA) and thiopurine treatments. Anti-tumour necrosis factor inhibitors (Anti-TNF inhibitors) are the agents of choice and vedolizumab could be considered as second-line biologic therapy.In the current case, we aim to describe a successful long-term treatment with vedolizumab in a 9-year-old boy with severe UC and primary non-response to infliximab. Concomitant azathioprine was used, and steroid refractoriness was also detected. Drug and anti-drug antibody levels were negative after infliximab induction so a switch to a 6-week-induction vedolizumab regimen followed by a maintenance regimen as a monotherapy was decided. The clinical response and tolerability to vedolizumab allowed long-term disease remission. Vedolizumab is currently non-authorised to treat paediatric patients and there is limited data on long-term treatments to date. This case contributes to the literature by adding evidence on the long-term efficacy and safety of vedolizumab in paediatric UC.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

Successful long-term treatment of paediatric ulcerative colitis with vedolizumab: a case report

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In a small pediatric study, four patients with ASUC refractory to steroids and TNF inhibitors were treated with VDZ. By the fourth dose, two (50%) showed a clinical response and avoided colectomy [47].…”

Section: Vedolizumab and Ustekinumabmentioning

confidence: 99%

Management of Hospitalized Patient with Ulcerative Colitis Refractory to Corticosteroids

Rabinowitz

Gold

Maser

2021

Management of Inpatient Inflammatory Bowel Disease

View full text Add to dashboard Cite

Response to vedolizumab for children with steroid‐refractory Ulcerative Colitis unresponsive to anti‐TNF

Cited by 2 publications

References 5 publications

Successful long-term treatment of paediatric ulcerative colitis with vedolizumab: a case report

Successful long-term treatment of paediatric ulcerative colitis with vedolizumab: a case report

Management of Hospitalized Patient with Ulcerative Colitis Refractory to Corticosteroids

Contact Info

Product

Resources

About